Introducing Souvenaid

- A medical nutrition product clinically proven to improve memory in patients with early Alzheimer’s disease\(^5,6\)
- Contains a unique, patented combination of nutrients designed to support synapse formation\(^15\)
- Well tolerated with \(>90\%\) product compliance\(^5,6\)

Recommend Souvenaid for your early AD patients

- To be taken once daily, every day
- Available in strawberry and vanilla flavours

Find out more at [www.Souvenaid.com](http://www.Souvenaid.com)

Souvenaid is a Food for Special Medical Purposes for the dietary management of early AD and must be used under medical supervision.

---

Synapse loss is one of the hallmarks of Alzheimer’s disease

Alzheimer’s disease (AD) is characterised by beta amyloid plaques, neurofibrillary tangles and loss of synapses.1

Synapse loss is believed to occur even before the onset of clinical symptoms of AD.2

There is a strong body of literature supporting the belief that patients with AD have specific nutritional needs.7-14

Souvenaid has been shown to improve memory in early AD.5,6

Souvenaid significantly improved the primary efficacy endpoint of memory (memory domain of the NTB) over 24-weeks.6

Souvenaid contains a unique, patented combination of nutrients designed to support synapse formation.15

Synapse loss is the hallmark of AD that correlates best with impaired memory performance.1,3,4

Memory performance declines as the number of synapses falls.

Correlation: r = 0.488

Adapted from Scheff et al. 2006.4

Adapted from Sperling et al., 2011.2